Navidea Biopharmaceuticals (NAVB) Earnings Date, Estimates & Call Transcripts → They say it’s ‘unstoppable’ – How I made 43,509% (From Investing Daily) (Ad) Free NAVB Stock Alerts $0.04 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share EarningsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueNAVB Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NAVB Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Investing DailyThey say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. NAVB Earnings Date and InformationNavidea Biopharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off prior year's report dates.Read More Get Navidea Biopharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for NAVB and its competitors with MarketBeat's FREE daily newsletter. Navidea Biopharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/9/2024Estimated)------- 11/14/2023Q3 2023-($0.02)($0.02)($0.02)--8/11/2023Q2 2023-($0.03)($0.03)($0.18)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)-- Get the Latest News and Ratings for NAVB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--They say it’s ‘unstoppable’ – How I made 43,509% (Ad)Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story.11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--They say it’s ‘unstoppable’ – How I made 43,509% (Ad)Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story.5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021($0.11)($0.08)+$0.03($0.08)$0.60 million$0.10 million They say it’s ‘unstoppable’ – How I made 43,509% (Ad)Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story.8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/10/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million 5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/10/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million Navidea Biopharmaceuticals Earnings - Frequently Asked Questions When is Navidea Biopharmaceuticals's earnings date? Navidea Biopharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off last year's report dates. Learn more on NAVB's earnings history. How much revenue does Navidea Biopharmaceuticals generate each year? Navidea Biopharmaceuticals (NYSE:NAVB) has a recorded annual revenue of $70,000.00. How much profit does Navidea Biopharmaceuticals generate each year? Navidea Biopharmaceuticals (NYSE:NAVB) has a recorded net income of -$15.18 million. NAVB has generated -$0.06 earnings per share over the last four quarters. More Earnings Resources from MarketBeat Related Companies: MYMD Earnings Date BMRA Earnings Date TRIB Earnings Date MBIO Earnings Date EVOK Earnings Date SNES Earnings Date UTRS Earnings Date FNCH Earnings Date AEMD Earnings Date GOVX Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NYSE:NAVB) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithJeff Bezos Just Humiliated Elon MuskInvestorPlaceBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
